Further trials of nifurtimox in mucocutaneous leishmaniasis.
At a dosage level of 8 to 10 mg/kg body-weight daily for 120 days nifurtimox was associated with clinical healing of cutaneous leishmaniasis in five of eight patients. At a dosage level of 20 mg/kg body-weight daily for 10 days in six of 10 patients the skin ulcer healed. Results and the reasons why both schemes are impracticable are briefly discussed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy*; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009547:Nifurtimox / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009581:Nitrofurans / Q000627:therapeutic use*
D009581:Nitrofurans; D009547:Nifurtimox